Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization

Tong-Hong Wang1,2, Chih-Ching Wu3,4,5,6, Kuo-Yen Huang7

  • 1Graduate Institute of Health Industry Technology and Research Center for Food and Cosmetic Safety, Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, 333, Taiwan.

Oncogenesis
|April 24, 2020
PubMed

Insights

Aberrant epidermal growth factor receptor (EGFR) distribution in non-small cell lung cancer (NSCLC) cells drives tumor progression. Targeting EGFR

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Aberrant subcellular localization of epidermal growth factor receptor (EGFR) is implicated in non-small cell lung cancer (NSCLC) pathogenesis.
  • Understanding the protein networks interacting with EGFR in different cellular compartments is crucial for elucidating its role in tumorigenesis.

Purpose of the Study:

  • To investigate the subcellular interactome of EGFR in NSCLC cells.
  • To identify protein networks associated with EGFR in cytosolic, mitochondrial, and nuclear fractions.
  • To explore the functional consequences of EGFR subcellular translocation on tumor progression.

Main Methods:

  • Utilized spectral counting and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify EGFR-interacting proteins.
  • Performed KEGG pathway analysis on identified protein sets from different cellular fractions.
  • Investigated the role of a specific nuclear EGFR-interacting protein, hnRNP A3, in regulating nuclear EGFR accumulation and tumor growth.

Main Results:

  • Identified 54, 77, and 63 EGFR-interacting proteins in cytosolic, mitochondrial, and nuclear fractions, respectively.
  • EGFR interactors in the cytosol are linked to ribosome pathways, in mitochondria to metabolic pathways (propanoate, fatty acid, amino acid metabolism), and in the nucleus to spliceosome pathways.
  • Downregulation of nuclear hnRNP A3 reduced nuclear EGFR accumulation and impaired tumor growth in vitro and in vivo.

Conclusions:

  • EGFR subcellular translocation and distribution are significant mechanisms in NSCLC development.
  • Specific protein networks associated with EGFR in different compartments play distinct roles in cancer progression.
  • Modulating nuclear EGFR accumulation via proteins like hnRNP A3 presents a potential therapeutic strategy for NSCLC.